PMS48 Tocilizumab in Methotrexate-Intolerant or Contraindicated Patients – A Cost-Utility Model for the UK

Value in Health - United Kingdom
doi 10.1016/j.jval.2012.08.1403
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

FRI0313 the Efficacy and Safety of Tocilizumab Therapy in Patients With Polymyalgia Rheumatica Who Were Resistant or Intolerant to Glucocorticoids and Additional Methotrexate

2017English

Mean Cost Per Number Needed to Treat With Tocilizumab Plus Methotrexate Versus Abatacept Plus Methotrexate in the Treatment of Rheumatoid Arthritis in Patients Previously Treated With Methotrexate

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2017English

Psy108 - Cost-Utility Analysis of Tocilizumab in Combination With Corticosteroids for the Treatment of Giant Cell Arteritis in Italian Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pms56 - Cost-Effectiveness Analysis of Subcutaneous Tocilizumab Without Methotrexate in Rheumatoid Arthritis Treatment

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pms44 - Cost-Effectiveness Analysis of Subcutaneous Tocilizumab Plus Methotrexate in Rheumatoid Arthritis Treatment

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

A UK-based Cost-Utility Analysis of Radiofrequency Ablation or Oesophagectomy for the Management of High-Grade Dysplasia in Barrett’s Oesophagus

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2010English

Cost Effectiveness of Drug Eluting Coronary Artery Stenting in a UK Setting: Cost-Utility Study

Heart
Cardiovascular MedicineCardiology
2006English

Peritoneal Dialysis and In-Centre Haemodialysis: A Cost-Utility Analysis From a UK Payer Perspective

Applied Health Economics and Health Policy
MedicineHealth PolicyEconomicsEconometrics
2014English

Pmu65 - Cost-Minimization Analysis of Smofkabiven® Central for Adult Patients With Impossible, Insufficient or Contraindicated Oral or Enteral Nutrition Versus Standard Endovascular Treatment in the Mexican Public Healthcare System

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy